Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
Federico M, Luminari S, Gobbi PG, Sacchi S, Di Renzo N, Lombardo M, Merli F, Baldini L, Stelitano C, Partesotti G, Polimeno G, Montanini A, Mammi C, Brugiatelli M. Federico M, et al. Among authors: partesotti g. Eur J Haematol. 2006 Mar;76(3):217-29. doi: 10.1111/j.1600-0609.2005.00609.x. Eur J Haematol. 2006. PMID: 16451396 Clinical Trial.
Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
Stelitano C, Baldini L, Pieresca C, Callea V, Angrilli F, Clò V, Partesotti G, Merli F, Cavanna L, Morabito F, Federico M, Brugiatelli M, Silingardi V. Stelitano C, et al. Among authors: partesotti g. Haematologica. 2000 Feb;85(2):154-9. Haematologica. 2000. PMID: 10681722 Free article.
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy.
Luminari S, Cesaretti M, Rashid I, Mammi C, Montanini A, Barbolini E, Bellei M, Pennese E, Sirotti MA, Marcheselli L, Partesotti G, Bari A, Maiorana A, Bonacorsi G, Federico M. Luminari S, et al. Among authors: partesotti g. Hematol Oncol. 2007 Dec;25(4):189-97. doi: 10.1002/hon.826. Hematol Oncol. 2007. PMID: 17654762
Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.
Marasca R, Maffei R, Morselli M, Zucchini P, Castelli I, Martinelli S, Fontana M, Ravanetti S, Curotti M, Leonardi G, Cagossi K, Partesotti G, Torelli G. Marasca R, et al. Among authors: partesotti g. J Mol Diagn. 2005 Nov;7(5):566-74. doi: 10.1016/S1525-1578(10)60589-2. J Mol Diagn. 2005. PMID: 16258154 Free PMC article.
Developing a robust sensor for infrared imaging bolometers.
Wurden GA, Partesotti G, Reimold F, Mukai K, Peterson BJ, Federici F. Wurden GA, et al. Among authors: partesotti g. Rev Sci Instrum. 2024 Sep 1;95(9):093503. doi: 10.1063/5.0219535. Rev Sci Instrum. 2024. PMID: 39225572
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Ferrario A, Merli F, Luminari S, Stelitano C, Mannina D, Russo M, Mazza P, Marcheselli L, Goldaniga MC, Federico M, Baldini L; Gruppo Italiano per lo Studio dei Linfomi. Ferrario A, et al. Ann Hematol. 2011 Mar;90(3):323-30. doi: 10.1007/s00277-010-1067-1. Epub 2010 Sep 17. Ann Hematol. 2011. PMID: 20848104 Clinical Trial.